Esophageal cancer

Active Research Protocols

  1. 06-C-0014 – Prospective Evaluation of Epigenetic Alterations in Patients with Thoracic Malignancies
  2. 07-C-0111 – A Pilot Study of Markers of Tumor Burden and Radiation Toxicity in the Blood, Urine, and Stool of Patients Receiving Radiotherapy for Gastrointestinal Malignancies
  3. 09-C-0100 – A Natural History Study of Patients Receiving High Dose Rate Brachytherapy
  4. 10-C-0138 – Allogeneic Tumor Cell Vaccine with Metronomic Oral Cyclophosphamide and Celecoxib as Adjuvant Therapy for Lung and Esophageal Cancers, Thymic Neoplasms, Thoracic Sarcomas, and Malignant Pleural Mesotheliomas
  5. 11-C-0041 – Epigenetically-Modified Autologous Tumor Cell Vaccines with ISCOMATRIX(TM) Adjuvant and Oral Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thoracic Sarcomas, and Malignant Pleural Mesotheliomas
  6. 12-C-0151 – Phase II Evaluation of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in Patients with Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum
NOTE: PDF documents require the free
Adobe Reader.
This page was last updated: January 24, 2014